U.S. Medical Equipment Stock News

AbbVie (ABBV) just received U.S. FDA approval for Decnupaz, the first antibody drug conjugate cleared to treat blastic plasmacytoid dendritic cell neoplasm, an ultra rare, aggressive blood cancer with limited options. See our latest analysis for AbbVie. AbbVie’s shares trade at US$218.63 after a 10.59% 1 month share price return, even though the stock is still down 4.66% year to date. The 1 year total shareholder return of 21.62% points to stronger underlying momentum building over time. If...

Earlier in May, Gilat Satellite Networks announced a milestone with Boeing to offer Gilat’s Sidewinder electronically steered antenna as a future line‑fit inflight connectivity option, while Boeing also secured FAA clearance to lift 737 Max output to 47 jets per month and confirmed an agreement for 200 aircraft with China. Together, these developments highlight Boeing’s efforts to restore operational momentum in commercial jets while deepening technology partnerships that could enhance...

PACCAR stock snapshot after recent performance PACCAR (PCAR) is drawing investor attention after a period where the stock is up about 22% over the past year but down around 6% over the past month and 11% over the past 3 months. At a recent close of US$112.22 and a market value near US$59.1b, PACCAR’s mix of truck manufacturing, parts distribution, and financial services provides several angles for evaluating its current pricing and recent volatility. See our latest analysis for PACCAR. For...

Over the past two weeks, Klarna Group (NYSE:KLAR) has announced multiple new partnerships across parking, retail, automotive services, vision care, and AI-driven shopping search. Arrive (EasyPark) will use Klarna to support parking payments in 15 European markets, while Lands' End expands Klarna's presence in U.S. retail. Partnerships with Tekion and EZContacts extend Klarna into automotive service department payments and the vision care market. An integration of Klarna's shopping search app...

Intellia Therapeutics recently reported positive phase III results for its CRISPR therapy lonvoguran ziclumeran in hereditary angioedema and began a rolling BLA submission to the FDA, while the FDA also lifted clinical holds on its other phase III candidate, nexiguran ziclumeran, allowing those trials to resume. These twin milestones not only move Intellia’s in vivo CRISPR programs closer to potential commercialization but also reduce clinical and regulatory uncertainty around its most...

Chubb (CB) stock has drawn investor interest after a recent pullback, with the share price closing at US$316.22 and sitting below some valuation estimates. This has put fresh attention on the insurer’s current fundamentals. See our latest analysis for Chubb. While the 1 day share price return declined 1.38% and the 90 day share price return is down 7.23%, Chubb’s 1 year total shareholder return of 8.90% and 5 year total shareholder return of 96.70% show that recent softness comes after a...

MACOM Technology Solutions Holdings (MTSI) drew investor attention after it agreed to long-term supply deals with IQE plc for epitaxial services and committed to an equity and convertible loan investment that includes a board seat. See our latest analysis for MACOM Technology Solutions Holdings. The stock has had a strong run, with the latest share price at US$391.09 and a 30 day share price return of 47.24%, while the 1 year total shareholder return is 216.67%. This indicates momentum that...

At its May 20, 2026 annual meeting, Five9 shareholders approved amendments to the company’s charter to declassify the Board of Directors and eliminate supermajority voting requirements, meaning all directors will now stand for election more frequently under standard voting thresholds. This shift materially strengthens shareholder rights and board accountability, potentially making Five9 more responsive to investor input on governance, capital allocation, and long-term corporate...

Clover Health Investments (CLOV) has recently drawn attention after a strong share price move, with the stock up 16% over the past week and about 58% over the past month. See our latest analysis for Clover Health Investments. That sharp 16.43% 1 day share price return and 58.33% 30 day share price return come on top of a 73.44% year to date share price return and a very large 3 year total shareholder return. This pattern suggests momentum has been building recently as investors reassess...

Momentus (MNTS) has drawn fresh attention after entering securities purchase agreements with existing institutional investors for a private placement of 2,942,000 shares. The transaction is expected to raise about US$25,000,000 in gross proceeds. See our latest analysis for Momentus. The private placement and recent shelf registrations have arrived after a sharp swing in sentiment, with the 30 day share price return of 278.91% and year to date share price return of 237.98% contrasting with a...

Investors may wish to note that the Chief Revenue Officer of TechTarget, Inc. , Steven Niemiec, recently netted US$95k...

Texas Instruments stock snapshot and recent performance Texas Instruments (TXN) has been drawing investor attention after a strong run in recent months, with the stock last closing at $315.95 and showing solid gains over the past year. Over the past week, Texas Instruments is up 5.88%, with the move extending a month gain of 19.23% and a past 3 months gain of 48.96%. The stock’s 1 year total return stands at 75.58%, while the 3 year and 5 year total returns are 96.19% and 95.80%...

Wondering if Forgent Power Solutions at around US$47.56 is offering value or stretching expectations? This article walks through what the current price might be telling you. The stock has eased about 2% over the past week, but is still up 28.9% over the past month and 64.0% year to date, which can change how you think about both upside and risk. Recent coverage has focused on Forgent Power Solutions as investors look more closely at power and grid related companies, with attention on how its...

The Surface Transportation Board has paused and conditionally accepted the proposed merger between Union Pacific and Norfolk Southern. The decision brings heightened regulatory scrutiny and organized opposition from multiple state Attorneys General. The review process is expected to be intensive, with a focus on competition and potential business impacts across freight markets. Union Pacific, NYSE:UNP, is entering this review with its stock at $267.0 and a 15.1% return year to date. The...

Hecla Mining (HL) is back in focus after recent share price moves, with the stock up 3.8% on the day and modest gains over the past week, despite a weaker past 3 months. See our latest analysis for Hecla Mining. At a share price of US$17.59, Hecla’s near term momentum has softened, with the share price return down 29.39% over the past 90 days, even though the 1 year total shareholder return is very large. If you are looking beyond Hecla and want to see what else is moving in precious metals,...

Webull (BULL) has caught investor attention after recent trading, with the stock closing at US$6.33 and showing mixed performance across different periods, including a decline over the past month and a gain over the past 3 months. See our latest analysis for Webull. Looking beyond the latest move to US$6.33, Webull’s share price return is down 22.71% year to date and the 1 year total shareholder return is down 49.12%, indicating momentum has been weak despite an 8.95% 3 month share price...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Recent performance context for Federal Agricultural Mortgage (AGM) Federal Agricultural Mortgage (AGM) has drawn fresh attention after a period of mixed share performance, with modest gains in the past week and month, alongside a decline over the past year and stronger multi‑year total returns. See our latest analysis for Federal Agricultural Mortgage. With the share price at US$179.50 and a 90 day share price return of 13.85%, but a 1 year total shareholder return that is slightly down,...

Why National Beverage stock is drawing attention National Beverage (FIZZ) is back on investors’ radar after a recent share price move, with returns over the past month and past 3 months prompting closer scrutiny of its fundamentals and valuation. See our latest analysis for National Beverage. At a recent share price of US$37.24, the stock has a 1 month share price return of 7.91% and a year to date share price return of 17.62%, yet the 1 year total shareholder return is down 16.95%. This...

In late May, a Blue Origin New Glenn rocket exploded during testing, raising questions about future launch availability for AST SpaceMobile. The incident follows the loss of a BlueBird satellite in April due to a separate launch failure that affected the company’s deployment schedule. AST SpaceMobile has already shifted its next BlueBird batch to a planned mid June Falcon 9 launch with SpaceX from Cape Canaveral. The stock, NasdaqGS:ASTS, last closed at $133.09, with very large 1 year...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Garrett...

Wondering if Vulcan Materials at a recent US$276.75 close is priced appropriately for its future or offering limited value? This article walks through what the numbers actually say about the stock. Recent returns have been mixed, with the stock up 5.6% over the past week, down 5.0% over the past month, down 5.4% year to date, and up 5.1% over the past year, which can signal changing views on both opportunity and risk. Recent news flow around Vulcan Materials has centered on ongoing interest...

Recent performance and scale Berkshire Hathaway (BRK.B) has drawn investor attention after recent trading, with the stock down around 5% over the past 3 months and about 4% year to date, closing at US$477.42. See our latest analysis for Berkshire Hathaway. For context, Berkshire Hathaway’s recent share price weakness has been relatively steady rather than abrupt, with a 90 day share price return of about a 5% decline, while the 3 year total shareholder return of around 48% reflects a stronger...

The United States market has shown robust performance recently, climbing 1.8% in the last seven days and rising 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, identifying small-cap stocks that are potentially undervalued and experiencing insider action can present unique opportunities for investors seeking to capitalize on growth prospects within emerging companies.